Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 4, 2013, Pages 825-833

  Han, Seongah ^a   Levoci, Lauretta ^a   Fischer, Paul ^a   Wang, Sheng Ping ^a   Gagen, Karen ^a   Chen, Ying ^a   Xie, Dan ^a   Fisher, Timothy ^a   Ehrhardt, Anka G ^a   Peier, Andrea M ^a   Johns, Douglas G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anacetrapib; Cholesteryl ester transfer protein; Endothelial cell; High density lipoprotein; Inflammation

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN ISOLATION; RANDOMIZED CONTROLLED TRIAL; SYRIAN HAMSTER; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHOLESTEROL ESTER TRANSFER PROTEINS; E-SELECTIN; ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, HDL; OXAZOLIDINONES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

CRICETINAE;

EID: 84873700254     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.12.008     Document Type: Article

References (30)

1. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J.P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, and B. Brewer Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122
2. M.J. Forrest, D. Bloomfield, R.J. Briscoe, R.N. Brown, A.M. Cumiskey, J. Ehrhart, J.C. Hershey, W.J. Keller, X. Ma, H.E. McPherson, E. Messina, L.B. Peterson, W. Sharif-Rodriguez, P.K.S. Siegl, P.J. Sinclair, C.P. Sparrow, A.S. Stevenson, S.Y. Sun, C. Tsai, H. Vargas, M. Walker, S.H. West, V. White, and R.F. Woltmann Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br. J. Pharmacol. 154 2008 1465 1473
3. M. DePasquale, G. Cadelina, D. Knight, W. Loging, S. Winter, E. Blasi, D. Perry, and J. Keiser Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors Drug Dev. Res. 70 2009 35 48
4. X. Hu, J.D. Dietz, C.S. Xia, D.R. Knight, W.T. Loging, A.H. Smith, H.D. Yuan, D.A. Perry, and J. Keiser Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
5. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.C. Tardif, and R.S. Wright Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome N. Engl. J. Med. 367 2012 2089 2099
6. E.A. Stein, E.M. Roth, J.M. Rhyne, T. Burgess, D. Kallend, and J.G. Robinson Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur. Heart J. 31 4 2010 480 488
7. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, and P. Barter Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
8. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, K.A. Krueger, M.D. Wang, M. Shao, B. Hu, E. McErlean, and S.E. Nissen Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 19 Nov 16 2011 2099 2100
9. L. Yvan-Charvet, N. Wang, and A.R. Tall Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses Arterioscler. Thromb. Vasc. Biol. 30 2010 139 143
10. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ. Res. 95 2004 764 772
11. A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab. 7 2008 365 375
12. A.R. Tall Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins J. Intern. Med. 263 2008 256 273
13. P.J. Barter, R. Puranik, and K.A. Rye New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease Curr. Cardiol. Rep. 9 2007 493 498
14. L. Yvan-Charvet, J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher, C.P. Sparrow, A.K. Taggart, and A.R. Tall Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler. Thromb. Vasc. Biol. 30 7 2010 1430 1438
15. J. Castro-Perez, F. Briand, K. Gagen, S.P. Wang, Y. Chen, D.G. McLaren, V. Shah, R.J. Vreeken, T. Hankemeier, T. Sulpice, T.P. Roddy, B.K. Hubbard, and D.G. Johns Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters J. Lipid Res. 52 11 Nov 2011 1965 1973
16. J.R. Nofer, S. Geigenmuller, C. Gopfert, G. Assmann, E. Buddecke, and A. Schmidt High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells Biochem. Biophys. Res. Commun. 310 2003 98 103
17. P.J. Barter, P.W. Baker, and K.A. Rye Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells Curr. Opin. Lipidol. 13 2002 285 288
18. G.W. Cockerill, K.A. Rye, J.R. Gamble, M.A. Vadas, and P.J. Barter High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler. Thromb. Vasc. Biol. 15 1995 1987 1994
19. R. Puranik, S. Bao, E. Nobecourt, S.J. Nicholls, G.J. Dusting, P.J. Barter, D.S. Celermajer, and K.A. Rye Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo Atherosclerosis 196 2008 240 247
20. -/- mice FASEB J. 14 2000 2032 2039
21. S. Yamagishi, H. Adachi, T. Matsui, K. Nakamura, M. Enomoto, A. Fukami, M. Otsuka, S. Kumagae, Y. Nanjo, and T. Imaizumi Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population Clin. Cardiol. 32 2009 E29 E32
22. R.M. Krauss, K. Wojnooski, J. Orr, J.C. Geaney, C.A. Pinto, Y. Liu, J.A. Wagner, J.M. Luk, A.O. Johnson-Levonas, M.S. Anderson, and H.M. Dansky Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the cholesteryl ester transfer protein inhibitor anacetrapib J. Lipid Res. 53 2012 540 547
23. S. Han, A.M. Flattery, D. McLaren, R. Raubertas, S.H. Lee, V. Mendoza, R. Rosa, N. Geoghagen, J.M. Castro-Perez, T.P. Roddy, G. Forrest, D. Johns, B.K. Hubbard, and J. Li Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples J. Cardiovasc. Transl. Res. 5 2012 75 83
24. H. Zhou, W. Li, S.P. Wang, V. Mendoza, R. Rosa, J. Hubert, K. Herath, T. McLaughlin, R.J. Rohm, M.E. Lassman, K.K. Wong, D.G. Johns, S.F. Previs, B.K. Hubbard, and T.P. Roddy Quantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water J. Lipid Res. 53 6 Jun 2012 1223 1231
25. A. Schumacher, I. Seljeflot, L. Sommervoll, B. Christensen, J.E. Otterstad, and H. Arnesen Increased levels of markers of vascular inflammation in patients with coronary heart disease Scand. J. Clin. Lab. Invest. 62 2002 59 68
26. H.H. Li, D.S. Lyles, W. Pan, E. Alexander, M.J. Thomas, and M.G. Sorci-Thomas ApoA-I structure on discs and spheres. Variable helix registry and conformational states J. Biol. Chem. 42 2002 39093 39101
27. T. Collins, M.A. Read, A.S. Neish, M.Z. Whitley, D. Thanos, and T. Maniatis Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers FASEB J. 9 1995 899 909
28. S. Mohan, N. Mohan, and E.A. Sprague Differential activation of NF-kappa B in human aortic endothelial cells conditioned to specific flow environments Am. J. Physiol. 273 1997 C572 C578
29. S.H. Park, J.H. Park, J.S. Kang, and Y.H. Kang Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression Int. J. Biochem. Cell Biol. 35 2003 168 182
30. C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C. Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein, A.M. Fogelman, T.F. Lüscher, and U. Landmesser Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J. Clin. Invest. 121 7 2011 2693 2708